The above results suggested that the CTLA4 inhibitor combined with other ICBs like PD-1 inhibitor nivolumab or LAG3 inhibitor may obtain a better therapeutic response in ccRCC, since that preclinical and clinical studies have provided evidence that combination inhibitor of CTLA4 and other ICBs can enhance the anti-tumor efficiency of CD8+ T cells [45, 46]. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.